- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03940625
Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping (ANKE)
May 19, 2022 updated by: Heinrich-Heine University, Duesseldorf
Anthracyclines (e.g.
Doxorubicin) are an important and highly effective chemotherapeutic.
They are used in various tumor entities and are established for breast cancer treatment.
The most significant prognostic side effect is cardiotoxicity, which occurs in up to 50 patients.
Female gender must be considered an independent risk factor for the incidence and severity of associated heart failure.
The aim of this study is to demonstrate that dose-dependent anthracycline-induced cardiotoxicity has a measurable effect on T2 mapping on MRI.
The second aim is to demonstrate if the combination of diastolic strain (echo and MRI) and T2 mapping can detect earlier anthracycline-induced myocardial damage than via the established method of the echocardiographic measurement of LV-EF and the conventional quantification of diastolic function.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
In order to answer the question, patients with breast cancer, who will undergo a chemotherapeutic treatment with antracycline, will be examined before chemotherapy (including cmr and echocardiography) and after chemotherapy at different times within one year.
Study Type
Interventional
Enrollment (Actual)
69
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dusseldorf, Germany, 40225
- Division of Cardiology, Pulmonary Disease and Vascular Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Planned therapy with an anthracycline and at least 1 year follow up
- >18 years of age
- written informed consent
Exclusion Criteria:
- prior cardiovascular disease
- diabetes mellitus
- previous therapy with anthracyclines
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
reduction of the left ventricular ejection fraction (LV-EF) by 10% to under 50%
Time Frame: after 12 months
|
volumetric determination of LV-EF
|
after 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
reduction of the left ventricular global longitudinal strain (GLS) by over 15%
Time Frame: after 12 months
|
determination of GLS via strain analysis
|
after 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 3, 2015
Primary Completion (ACTUAL)
April 30, 2022
Study Completion (ACTUAL)
April 30, 2022
Study Registration Dates
First Submitted
May 6, 2019
First Submitted That Met QC Criteria
May 6, 2019
First Posted (ACTUAL)
May 7, 2019
Study Record Updates
Last Update Posted (ACTUAL)
May 25, 2022
Last Update Submitted That Met QC Criteria
May 19, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
Clinical Trials on Cardiac MRI and echocardiography, laboratory parameters
-
Oncology Institute of Southern SwitzerlandCardiocentro Ticino; North Estonia Medical Centre; Fondazione IRCCS Policlinico...RecruitingCardiotoxicitySwitzerland
-
Assiut UniversityRecruiting
-
Assiut UniversityCompleted
-
Wonju Severance Christian HospitalRecruitingMyocardial Injury | Complications | Therapy | Carbon Monoxide Poisoning | Image, Body | Neurologic Deficits | Prognostic FactorsKorea, Republic of
-
Karim WAHBIInstitut de Myologie, FranceUnknownHeart Failure | Dilated Cardiomyopathy | Lef Ventricular DysfunctionFrance
-
Ayham DaherRecruitingIdiopathic Pulmonary Fibrosis | COPD | Bronchial AsthmaGermany
-
University of LeicesterNational Institute for Health Research, United KingdomCompletedPatients With Heart Failure and Preserved Ejection Fraction - HFpEF | Patients With Heart Failure With Reduced Ejection Fraction - HFrEF | Healthy Controls Group - Age and Sex-matched
-
Hari NarayanRecruitingHeart Failure | Cardiotoxicity | Pediatric CancerUnited States
-
Wonju Severance Christian HospitalNational Research Foundation of KoreaCompletedMyocardial Injury | Carbon Monoxide Poisoning | Image, BodyKorea, Republic of
-
Alejandro Rodriguez Oviedo , MDTerminatedMyocardial Ischemia | Pneumonia, PneumococcalSpain